LipoScience seeks to raise $86m in IPO to expand sales
This article was originally published in Clinica
Executive Summary
LipoScience, a US developer of a test for managing patients' risk of cardiovascular disease, is aiming to raise $86.3m in an initial public offering on the Nasdaq.